ESR1 and ovarian carcinoma: For example, 17β-estradiol (E2) treatment can induce EMT in ERα positive BG-1 ovarian cancer cells via ERα activation, while overexpression of ERβ or treatment with ERβ agonist DPN completely inhibited E2-induced EMT in these cells [7].